Alnylam Pharmaceuticals, Inc. vs The Vita Coco Company Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.03B), while The Vita Coco Company Inc trades at $64.43 (market cap $3.63B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 8× The Vita Coco Company Inc's market cap, and The Vita Coco Company Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | COCO | |
|---|---|---|
Market Cap | $29.03B | $3.63B |
Sector | Health | Technology |
52-Week High | $491.22 | $84.02 |
52-Week Low | $205.48 | $32.37 |
Enterprise Value | $26.99B | $3.37B |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $219.20, down 1.43% amid bearish technical signals and recent earnings volatility. The stock faces near-term pressure from a Q2 2026 EPS miss and lowered 2026 sales guidance, but maintains strong fundamentals with 2025 revenue of $3.71B and net income of $313.75M. Analyst consensus remains bullish with a $370.07 price target, though multiple law firms are investigating potential securities fraud as reported by PRNewsWire and GlobeNewsWire in early August 2026.
Outlook is mixed: robust revenue growth and high profitability margins support long-term potential, but legal uncertainties and recent earnings disappointments pose significant risks. The stock's current valuation (P/E 38.19) reflects growth expectations, yet investor caution is warranted given technical bearishness and ongoing investigations.
The Vita Coco Company (COCO) trades at $62.25, down 2.92% over 24 hours, with a bullish technical signal driven by oversold RSI readings and support near $62. Fundamentally, Q2 2026 earnings beat expectations with EPS of $0.82 versus $0.56 estimated, while revenue grew 28% year-over-year to $216 million. The company raised full-year 2026 guidance, reflecting strong demand and the Copra acquisition.
Outlook remains positive with 60% analyst buy ratings and an $80.67 consensus price target, implying ~30% upside. Key risks include margin pressure from rising costs and capacity constraints. Growth catalysts include international expansion and health-focused innovation in the beverage sector.
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →